【摘要】 代谢相关脂肪性肝病（MAFLD）是一种与胰岛素抵抗（IR）密切相关的代谢性疾病。与非糖尿病的MAFLD患者相比，合并有2型糖尿病（T2DM）的MAFLD患者发展为脂肪性肝炎和肝脏晚期纤维化的风险更高。目前还没有针对该病的特异性药物，而胰岛素抵抗可能是连接MAFLD与T2DM的中心环节。不同类别降糖药物作用机制既有区别也有重叠，本文就不同降糖药物对MAFLD合并T2DM患者肝脏疾病的治疗作用作一综述，以为临床治疗该疾病提供参考。更多还原

【Abstract】 Metabolism-related fatty liver disease(MAFLD) is a kind of metabolic disease closely related to insulin resistance(IR). Compared with non-diabetic patients with MAFILD, patients with MAFILD with type 2 diabetes mellitus(T2 DM) have a higher risk of developing steatohepatitis and advanced liver fibrosis. There is a lack of specific drug treatment for this condition, insulin resistance may be the central link between MAFLD and T2 DM. Different hypoglycemic drugs have different and overlapping mechanisms. This paper reviews the therapeutic effects of different hypoglycemic drugs on liver diseases in patients with MAFLD complicated with T2 DM, so as to provide reference for clinical treatment of the disease.更多还原